Main > > >OMALIZUMAB. *

---

Allergy>Asthma. TREAT.: OmalizuMAb for SubCutaneous Use.
Mechanism: Anti-IgE MAb
USA Approval >12 Years : 2003.
USA Approval 06-11 Years: 2016. 07.07.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 04.01



>OMALIZUMAB. *'s products
This section has no products